

# pharmacology



By:.



Team of pharmacology

# 2<sup>nd</sup> pharmacology lecture: Skeletal Muscle Relaxants




## Lecture's objectives:

1. Be familiar to the classification of skeletal muscle relaxants.
2. The uses and classification (**Competitive and depolarizing**) of neuromuscular blockers.
3. Mechanism of action, pharmacokinetics, pharmacological action and examples of competitive and depolarizing neuromuscular blockers.



## uses of neuromuscular blockers



## Competitive NM blockers: mechanism of action

- ▶ Are competitive antagonists
- ▶ Compete with Ach for the nicotinic receptors present in post-junctional membrane of motor end plate.
- ▶ No depolarization of post-junctional membrane

لان اذا قل cholinesterase بيزيد الـ ( ACH ) لان  
الـ cholinesterase يدمر الـ ( ACH )  
بالتالي اذا زاد ACH راح  
يسوي displacement لـ competitive blocker

## Pharmacokinetics

### Pharmacokinetics

- ▶ They are polar compounds (have low V.D.)
  - inactive orally & taken parenterally
  - Do not cross placenta & CNS
- ▶ Metabolism depend upon kidney or liver

### Except

*Mivacurium (degraded by pseudo cholinesterases)*

*Atracurium (spontaneous degradation in blood)*

## Pharmacological actions:

- ▶ Skeletal muscle relaxation.
- ▶ They produce different effects on CVS
- ▶ Some release histamine and produce hypotension
  - d.Tubocurarine
  - Atracurium
  - Mivacurium
- ▶ Others produce tachycardia (↑ H.R)
  - Pancuronium

## Depolarizing Neuromuscular Blockers

### Mechanism of Action

- ▶ combine with nicotinic receptors in post-junctional membrane of neuromuscular junction → initial depolarization of motor end plate → muscle twitching → Persistent depolarization → paralysis

<i>Drug</i>	<i>Duration</i>	<i>Side effects</i>	<i>Notes</i>
<b>Tubocurarine</b>	<b>Long 1-2 h</b>	<b>Hypotension</b>	<b># Renal failure</b>
<b>Pancuronium</b>	<b>Long 1-2 h</b>	<b>Tachycardia</b>	<b># Renal failure</b>
<b>Atracurium</b>	<b>Short 30 min.</b>	<b>Transient hypotension Histamine release</b>	<b>Spontaneous degradation Used in liver and kidney failure</b>
<b>Vecuronium</b>	<b>Short 40 min.</b>	<b>Few side effects</b>	<b># Liver failure</b>
<b>Mivacurium</b>	<b>Short 15 min.</b>	<b>Transient hypotension Histamine release</b>	<b>Metabolized by pseudocholinesterase # Choline esterase deficiency</b>
<b>Succinyl choline</b>	<b>Short 10 min.</b>	<b>Hyperkalemia Arrhythmia Increase IOP</b>	<b># CVS Diseases # Glaucoma # Liver disease</b>

### Malignant hyperthermia

- ▶ Is a rare inherited condition that occurs upon administration of drugs as:
  - general anesthesia e.g. halothane
  - neuromuscular blockers e.g. suxamethonium
- ▶ Inability to bind calcium by sarcoplasmic reticulum in some patients due to genetic defect
- ▶ ↑ Ca release, intense muscle spasm, hyperthermia

**Spasmolytics** : They reduce muscle spasm in spastic states

Baclofen:

- ▶ Centrally acting
- ▶ GABA agonist – acts on spinal cord.

Diazepam (**Benzodiazepines**):

- ▶ Centrally acting
- ▶ facilitate GABA action on CNS.

Dantrolene:

- ▶ direct action on skeletal muscles.
- ▶ Used in treatment of malignant hyperthermia

Uses of spasmolytics

They reduce muscle spasm in spastic states produced by :

- Spinal cord injury
- Cerebral stroke
- Cerebral palsy

## Dantrolene

Mechanism of Action

- ▶ It interferes with the release of calcium from its stores in skeletal muscles (sarcoplasmic reticulum).
- ▶ It inhibits excitation-contraction coupling in the muscle fiber.

Uses

Malignant Hyperthermia.

Spastic states.

IV, orally  $t_{1/2} = 8 - 9$  hrs.